Pacific Biosciences of California, Inc. Operating Lease Cost
Pacific Biosciences of California, Inc. (PACB) reported Operating Lease Cost of $9.30 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-02-25
- Pacific Biosciences of California, Inc. operating lease, cost for the quarter ending 2025-03-31 was $2.00M, a 23.08% decline year-over-year.
- Pacific Biosciences of California, Inc. operating lease, cost for the quarter ending 2024-03-31 was $2.60M.
- Pacific Biosciences of California, Inc. operating lease, cost for the quarter ending 2021-12-31 was $2.50M, a 66.67% increase year-over-year.
- Pacific Biosciences of California, Inc. operating lease, cost for the quarter ending 2021-09-30 was $1.60M, a 0.00% change year-over-year.
- Pacific Biosciences of California, Inc. operating lease, cost for fiscal 2025 was $9.30M, a 35.86% decline from fiscal 2024.
- Pacific Biosciences of California, Inc. operating lease, cost for fiscal 2024 was $14.50M, a 39.42% increase from fiscal 2023.
- Pacific Biosciences of California, Inc. operating lease, cost for fiscal 2023 was $10.40M, a 0.95% decline from fiscal 2022.
- Pacific Biosciences of California, Inc. operating lease, cost for fiscal 2022 was $10.50M, a 45.83% increase from fiscal 2021.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|
| 2025-12-31 | $9.30M 10-K · filed 2026-02-25 | |||
| 2025-03-31 | $2.00M 10-Q · filed 2025-05-12 | |||
| 2024-12-31 | $14.50M 10-K · filed 2026-02-25 | |||
| 2024-03-31 | $2.60M 10-Q · filed 2025-05-12 | |||
| 2023-12-31 | $10.40M 10-K · filed 2025-03-17 | |||
| 2022-12-31 | $10.50M 10-K · filed 2024-02-28 | |||
| 2021-12-31 | $2.50M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $4.10M derived: sum of 2 quarters · filed 2023-02-28 | $5.70M derived: sum of 3 quarters · filed 2023-02-28 | $7.20M 10-K · filed 2023-02-28 |
| 2021-09-30 | $1.60M 10-Q · filed 2021-11-05 | $3.20M derived: sum of 2 quarters · filed 2021-11-05 | $4.70M 10-Q · filed 2021-11-05 | $6.30M derived: sum of 4 quarters · filed 2022-02-28 |
| 2021-06-30 | $1.60M 10-Q · filed 2021-08-06 | $3.10M 10-Q · filed 2021-08-06 | $4.70M derived: sum of 3 quarters · filed 2022-02-28 | $6.30M derived: sum of 4 quarters · filed 2022-02-28 |
| 2021-03-31 | $1.60M 10-Q · filed 2021-05-06 | $3.10M derived: sum of 2 quarters · filed 2022-02-28 | $4.70M derived: sum of 3 quarters · filed 2022-02-28 | $6.30M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-12-31 | $1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $3.10M derived: sum of 2 quarters · filed 2022-02-28 | $4.70M derived: sum of 3 quarters · filed 2022-02-28 | $6.20M 10-K · filed 2022-02-28 |
| 2020-09-30 | $1.60M 10-Q · filed 2021-11-05 | $3.20M derived: sum of 2 quarters · filed 2021-11-05 | $4.70M 10-Q · filed 2021-11-05 | $6.30M derived: sum of 4 quarters · filed 2021-11-05 |
| 2020-06-30 | $1.60M 10-Q · filed 2021-08-06 | $3.10M 10-Q · filed 2021-08-06 | $4.70M derived: sum of 3 quarters · filed 2021-08-06 | $6.30M derived: sum of 4 quarters · filed 2021-08-06 |
| 2020-03-31 | $1.60M 10-Q · filed 2021-05-06 | $3.10M derived: sum of 2 quarters · filed 2021-05-06 | $4.70M derived: sum of 3 quarters · filed 2021-05-06 | $6.30M derived: sum of 4 quarters · filed 2021-05-06 |
| 2019-12-31 | $1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $3.10M derived: sum of 2 quarters · filed 2021-02-26 | $4.70M derived: sum of 3 quarters · filed 2021-02-26 | $6.20M 10-K · filed 2021-02-26 |
| 2019-09-30 | $1.60M 10-Q · filed 2020-11-03 | $3.20M derived: sum of 2 quarters · filed 2020-11-03 | $4.70M 10-Q · filed 2020-11-03 | |
| 2019-06-30 | $1.60M 10-Q · filed 2020-08-06 | $3.10M 10-Q · filed 2020-08-06 | ||
| 2019-03-31 | $1.60M 10-Q · filed 2020-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B |